(Total Views: 524)
Posted On: 12/31/2020 2:26:14 PM
Post# of 154719
“Look back further.”
You said a dozen GvHD trials were discontinued this year and that was incorrect. If I look back further, I see the DSMCs recommendation to halt the trial due to futility and NP’s history of hiding bad news (at the bottom of PRs). Again, preclinical data was excellent for GvHD and I hope the trial isn’t permanently discontinued, but I have my doubts. Leronlimab is destined to fail an indication no matter how detailed the 50+ disease list is.
You said a dozen GvHD trials were discontinued this year and that was incorrect. If I look back further, I see the DSMCs recommendation to halt the trial due to futility and NP’s history of hiding bad news (at the bottom of PRs). Again, preclinical data was excellent for GvHD and I hope the trial isn’t permanently discontinued, but I have my doubts. Leronlimab is destined to fail an indication no matter how detailed the 50+ disease list is.
(2)
(3)
